The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin

Annals of Pharmacotherapy

Volumn 38, Issue 2, 2004, Pages 277-285

  Ito, Matthew K ^a,b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Atherogenic dyslipidemia; HDL cholesterol; LDL particle size; Metabolic syndrome; Niacin; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ATHEROGENESIS; CORONARY ARTERY OBSTRUCTION; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MEDLINE; METABOLIC SYNDROME X; PARTICLE SIZE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIACIN; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 1642499297     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D218     Document Type: Review

References (57)

1. 2002 Heart and stroke statistical update. Dallas: American Heart Association, 2001.
2. Foot DK, Lewis RP, Pearson TA, Beller GA. Demographics and cardiology, 1950-2050. J Am Coll Cardiol 2000;35:1067-81.
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
4. Shepherd J, Cobbe SM. Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
6. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
10. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
12. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998;14(suppl B):14B-7B.
13. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998:19(suppl M):M8-M14.
14. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
15. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol 1999;84(1 suppl 1):28-32.
16. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993;71:9B-14B.
17. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996;45(suppl 3):S27-30.
18. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50.
19. Ginsberg HN, Goldberg IJ. Disorders of intermediary metabolism: disorders of lipoprotein metabolism. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001:2245-57.
20. Rosenson RS, Lowe GDO. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998;140:271-80.
21. Libby P. The pathogenesis of atherosclerosis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001:1377-82.
22. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
23. Meigs JB. Epidemiology of the metabolic syndrome, 2002. Am J Manag Care 2002;8(11 suppl):S283-92.
24. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16,
25. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
26. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al, Relation of gemfibrozil treatment and lipid levels with major coronary events, VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.
27. Robins SJ, Collins D, Rubins HB. Diabetes, hyperinsulinemia and recurrent coronary events in the VA-High Density Lipoprotein Intervention Trial (VA-HIT) (abstract 4069). Circulation 2002;102:11-847.
28. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
29. Zhao XQ, Morse J, Chait A, Fisher L, Dowdy A, Albers JJ. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome (abstract 1130-73). J Am Coll Cardiol 2002;39(suppl A):242A.
30. Laaksonen DE, Lakka H-M, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-7.
31. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
32. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-81.
33. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979;60:427-39.
34. Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2:36-46.
35. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76.
36. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO Jr, Harper WL, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am J Cardiol 2002;89:672-8.
37. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72.
38. Pieper JA. Understanding niacin formulations. Am J Manag Care 2002;8(12 suppl):S308-14.
39. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
40. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000;86(suppl 12A):35L-40L.
41. Morgan JM, Capuzzi DM, Guyton JR, Centor RM, Goldberg RM, Robbins DC, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
42. Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5.
43. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U.
44. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992;34:165-8.
45. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-6.
46. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000;284:1263-70.
47. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002;162:1568-76.
48. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
49. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
50. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project (abstract 3138). Circulation 2002;106(suppl II):II-636.
51. Morse JS, Brown BG, Zhao XQ, Fisher L, Chait A, Dowdy A, et al. Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDLc and diabetes mellitus or impaired fasting glucose (abstract 842-3). J Am Coll Cardiol 2001;37(suppl A):262A.
52. Nyman JA, Martinson MS, Nelson D, Nugent S, Collins D, Wittes J, et al. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. Arch Intern Med 2002;162:177-82.
53. Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50.
54. Bjorholt I, Andersson FL, Kahan T, Ostergren J. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Intern Med 2002;251:508-17.
55. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:47-74.
56. Olson BM, Malone DC. Modelling the cost-effectiveness of doubling atorvastatin's dose versus adding niacin ER. Formulary 2001;36:730-46.
57. 2002 Drug topics red book. Montvale, NJ: Medical Economics, 2002.